Video Series

Bruce Sherman, MD, FCCP, FACOEM, underlines the impact of health inequities for patients diagnosed with psoriasis.

Maria Lopes, MD, MS, provides an overview of the PASI scoring system.

Amy McMichael, MD, discusses the impact of psoriasis on a patient’s quality of life.

Ryan Haumschild, PharmD, MS, MBA, leads a panel discussion highlighting the current prevalence of psoriasis.

Dr Brinton provides insights regarding prognosis for patients with HoFH.

Eliot Brinton, MD, opens a discussion surrounding the treatment landscape for patients with homozygous familial hypercholesterolemia (HoFH).

David Lieberman, MD, PhD, reviews the potential role and the goals of gene therapy in the treatment of Rett syndrome.

In their closing thoughts, experts emphasize their optimism regarding the direction of LN treatment strategies and resources.

Drs Wells and Larranaga discuss unmet needs in the treatment landscape for patients with lupus nephritis.

Constructive advice on improving the Enhancing Oncology Model (EOM) from our expert panel.

The Enhancing Oncology Model allows pooling of groups of practices for quality measurement, which was not permitted under the OCM.

Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.

Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022.

Patient education is critical for self-monitoring of COPD disease progression.

An expert panel discusses appropriate transitions and adjustments to COPD treatment approaches.

Medical experts share considerations for early intervention in patients with diagnoses of diabetes.

Medical experts navigate risk factors associated with diabetes.

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).

Asking for help to prepare for the Enhancing Oncology Model (EOM) and 2-sided risk is advised, say panelists experienced with the Oncology Care Model (OCM).

As terms for Monthly Enhanced Oncology Services (MEOS) payments are set to change under the EOM, panelists worry that the barriers to entry to value-based care will be too high for practices that did not participate in the OCM.

In her final thoughts regarding gastroesophageal cancer, Laura Bobolts, PharmD, BCOP, overviews patient support services and programs.

Laura Bobolts, PharmD, BCOP, shares her perspective surrounding cost-effective analyses surrounding GI and esophageal cancers.

Laura Bobolts, PharmD, BCOP, discusses GI and esophageal cancer treatment pathway decisions.

Expert panelists consider factors affecting treatment adherence for patients with MDD.

Drs Weaver and Chitre illustrate a population health approach strategy for MDD.

Jorge Larranaga, MD, discusses the AURORA 2 study and its emphasis on voclosporin.

Belimumab and voclosporin are highlighted as key contributors to the lupus nephritis treatment landscape.